Innovating Works

A2F ASSOCIATES

Desconocido
CardioReGenix: CardioReGenix Development of Next Generation Gene Therapies for Cardiovascular Disease A2F ASSOCIATES LIMITED participó en un H2020: H2020-SC1-BHC-2018-2020 WHO estimates 17.7 million people die each year from cardiovascular disease (CVD), an estimated 31% of all deaths worldwide. While progress...
2018-11-21 - 2024-06-30 | Financiado
ReGenHeart: Clinical development and proof of principle testing of new regenerative VEGF D therapy for cost effe... A2F ASSOCIATES LIMITED participó en un H2020: H2020-SC1-2016-2017 Chronic angina pectoris is a debilitating chronic disease, a subgroup of these patients suffers from refractory angina which unfortunately c...
2016-12-01 - 2022-12-31 | Financiado
T2DSystems: Development of a systems biomedicine approach for risk identification prevention and treatment of t... A2F ASSOCIATES LIMITED participó en un H2020: H2020-PHC-2014-2015 Type 2 diabetes (T2D) is a major public health problem, affecting 55 million European citizens. T2D ensues in individuals who develop a prog...
2015-12-09 - 2019-12-31 | Financiado
BOOSTB4: Boost Brittle Bones Before Birth A2F ASSOCIATES LIMITED participó en un H2020: H2020-PHC-2014-2015 Osteogenesis imperfecta (OI) is, in its severe forms, a devastating inherited disorder characterised by brittle bones. A person with severe...
2015-09-11 - 2022-12-31 | Financiado
CARBALIVE: Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of live... A2F ASSOCIATES LIMITED participó en un H2020: H2020-PHC-2014-2015 Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-c...
2015-04-07 - 2021-01-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.